Quoin Pharmaceuticals reported a net loss of $3.9 million for the third quarter of 2025 and a cumulative loss of $11.5 million for the nine‑month period ending September 30, 2025. The loss widened from $2.3 million for the same quarter and $6.7 million for the nine‑month period in 2024, reflecting a 63% increase in research and development expenses as the company pushes its lead asset, QRX003, toward pivotal trials. The company generated no revenue, a typical profile for a clinical‑stage biotech, and held $5.4 million in cash, cash equivalents and marketable securities as of September 30, 2025, a balance that, when combined with the new financing, is expected to support operations through 2027.
The company closed a private‑placement financing that could raise up to $105.3 million, comprising an upfront $16.6 million and an additional $88.7 million contingent on warrant exercise. In October, Quoin received $3.3 million from warrant exercises, bringing total capital raised to $20 million to date. The infusion extends the company’s runway, allowing it to fund the ongoing development of QRX003 for Netherton Syndrome, expand its Peeling Skin Syndrome program, and advance a topical rapamycin platform.
Sally Lawlor was appointed chief financial officer, bringing a track record of financial stewardship and commercial readiness. Her appointment signals a strategic focus on strengthening the leadership team as the company prepares for the next phase of growth and the anticipated pivotal milestones for QRX003.
The company’s clinical pipeline remains centered on rare dermatologic disorders. QRX003, an oral therapy for Netherton Syndrome, has received FDA orphan drug designation and is entering pivotal enrollment in Q4 2025. Parallel programs in Peeling Skin Syndrome and topical rapamycin are being expanded to diversify the pipeline and address unmet medical needs.
Dr. Michael Myers, CEO, highlighted the company’s momentum, noting “the third quarter of 2025 has been a period of significant momentum and strategic advancement for Quoin Pharmaceuticals.” He added that the new CFO appointment and the private‑placement financing reinforce the company’s capacity to execute on its clinical roadmap and prepare for commercialization.
The increase in net loss is driven primarily by higher R&D spending, a common trend for companies advancing clinical candidates. However, the private‑placement financing mitigates cash pressure, providing a multi‑year runway that supports the company’s strategic objectives. The orphan drug designation for QRX003 enhances the asset’s commercial potential and positions Quoin favorably within the niche but critical rare‑disease market, where investor confidence is high and the pathway to approval is well defined.
Investors responded positively to the financing announcement, reflecting confidence in Quoin’s pipeline and the strategic leadership changes. The company’s focus on rare diseases, combined with a debt‑free balance sheet and a robust capital raise, underscores its long‑term growth prospects.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.